Arsenic oxide targets stem cell marker CD133/prominin-1 in gallbladder carcinoma

Cancer Letters

Volumn 310, Issue 2, 2011, Pages 181-187

  Ai, Zhilong ^a   Pan, Hongtao ^a   Suo, Tao ^a   Lv, Chentao ^a   Wang, Yueqi ^a   Tong, Saixiong ^a   Liu, Houbao ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

AKT; Apoptosis; Arsenic trioxide; CD133; Gallbladder carcinoma

Indexed keywords

ARSENIC TRIOXIDE; CD133 ANTIGEN; PROMININ 1; PROTEIN KINASE B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVATION; GALLBLADDER CARCINOMA; GENE EXPRESSION REGULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GALLBLADDER NEOPLASMS; GLYCOPROTEINS; HUMANS; NEOPLASTIC STEM CELLS; OXIDES; PEPTIDES; PLASMIDS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 80051700609     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.06.035     Document Type: Article

References (44)

1. Antman K.H. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 2001, 6(Suppl. 2):1-2.
2. Shen Y., Shen Z.X., Yan H., Chen J., Zeng X.Y., Li J.M., Li X.S., Wu W., Xiong S.M., Zhao W.L., Tang W., Wu F., Liu Y.F., Niu C., Wang Z.Y., Chen S.J., Chen Z. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 2001, 15:735-741.
3. Chung W.H., Sung B.H., Kim S.S., Rhim H., Kuh H.J. Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro. Int. J. Oncol. 2009, 34:1669-1679.
4. 3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res. 2001, 61:5432-5440.
5. Park W.H., Seol J.G., Kim E.S., Hyun J.M., Jung C.W., Lee C.C., Kim B.K., Lee Y.Y. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 2000, 60:3065-3071.
6. Hyun Park W., Hee Cho Y., Won Jung C., Oh Park J., Kim K., Hyuck Im Y., Lee M.H., Ki Kang W., Park K. Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem. Biophys. Res. Commun. 2003, 300:230-235.
7. Woo S.Y., Lee M.Y., Jung Y.J., Yoo E.S., Seoh J.Y., Shin H.Y., Ahn H.S., Ryu K.H. Arsenic trioxide inhibits cell growth in SH-SY5Y and SK-N-AS neuroblastoma cell lines by a different mechanism. Pediatr. Hematol. Oncol. 2006, 23:231-243.
8. Li X., Ding X., Adrian T.E. Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression. Pancreas 2003, 27:174-179.
9. Park S.G., Jung J.J., Won H.J., Kang M.S., Seo S.K., Choi I.W., Eun C.K., Ahn K.J., Park C.W., Lee S.W., Lew Y.S., Bae I.J., Choi I.H. Tetra-arsenic oxide (Tetras) enhances radiation sensitivity of solid tumors by anti-vascular effect. Cancer Lett. 2009, 277:212-217.
10. Au W.Y., Hon C., Yau K., Lai W.W., Fong B.M., Tam S., Kwong Y.L. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia. Am. J. Hematol. 2009, 84:699.
11. Ammatuna E., Montefusco E., Pacilli M., Divona M., Ardiri D., Centonze D., Lo-Coco F. Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone. Leuk. Lymphoma 2009, 50:1217-1218.
12. Ai Z., Lu W., Ton S., Liu H., Sou T., Shen Z., Qin X. Arsenic trioxide-mediated growth inhibition in gallbladder carcinoma cells via down-regulation of cyclin D1 transcription mediated by Sp1 transcription factor. Biochem. Biophys. Res. Commun. 2007, 360:684-689.
13. Ai Z., Lu W., Qin X. Arsenic trioxide induces gallbladder carcinoma cell apoptosis via downregulation of Bcl-2. Biochem. Biophys. Res. Commun. 2006, 348:1075-1081.
14. Campos B., Herold-Mende C.C. Insight into the complex regulation of CD133 in glioma. Int. J. Cancer 2011, 128:501-510.
15. Corbeil D., Marzesco A.M., Wilsch-Brauninger M., Huttner W.B. The intriguing links between prominin-1 (CD133), cholesterol-based membrane microdomains, remodeling of apical plasma membrane protrusions, extracellular membrane particles, and (neuro)epithelial cell differentiation. FEBS Lett. 2010, 584:1659-1664.
16. Ferrandina G., Petrillo M., Bonanno G., Scambia G. Targeting CD133 antigen in cancer. Exp. Opin. Ther. Targets 2009, 13:823-837.
17. Wu Y., Wu P.Y. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Develop. 2009, 18:1127-1134.
18. Bidlingmaier S., Zhu X., Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J. Mol. Med. (Berlin, Germany) 2008, 86:1025-1032.
19. Mizrak D., Brittan M., Alison M.R. CD133: molecule of the moment. J. Pathol. 2008, 214:3-9.
20. Yin S., Li J., Hu C., Chen X., Yao M., Yan M., Jiang G., Ge C., Xie H., Wan D., Yang S., Zheng S., Gu J. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int. J. Cancer 2007, 120:1444-1450.
21. Suetsugu A., Nagaki M., Aoki H., Motohashi T., Kunisada T., Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem. Biophys. Res. Commun. 2006, 351:820-824.
22. Haraguchi N., Utsunomiya T., Inoue H., Tanaka F., Mimori K., Barnard G.F., Mori M. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006, 24:506-513.
23. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
24. Ma S., Lee T.K., Zheng B.J., Chan K.W., Guan X.Y. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008, 27:1749-1758.
25. Dong K., Wang R., Wang X., Lin F., Shen J.J., Gao P., Zhang H.Z. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells. Breast Cancer Res. Treat. 2009, 113:443-456.
26. Tokunaga E., Oki E., Egashira A., Sadanaga N., Morita M., Kakeji Y., Maehara Y. Deregulation of the Akt pathway in human cancer. Curr. Cancer Drug Targets 2008, 8:27-36.
27. Song G., Ouyang G., Bao S. The activation of Akt/PKB signaling pathway and cell survival. J. Cell. Mol. Med. 2005, 9:59-71.
28. Park C.Y., Tseng D., Weissman I.L. Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol. Ther. 2009, 17:219-230.
29. Kitamura H., Okudela K., Yazawa T., Sato H., Shimoyamada H. Cancer stem cell: implications in cancer biology and therapy with special reference to lung cancer. Lung Cancer (Amsterdam, Netherlands) 2009, 66:275-281.
30. Ghotra V.P., Puigvert J.C., Danen E.H. The cancer stem cell microenvironment and anti-cancer therapy. Int. J. Radiat. Biol. 2009, 85:955-962.
31. Soignet S.L. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist 2001, 6(Suppl. 2):11-16.
32. Zhu X.H., Shen Y.L., Jing Y.K., Cai X., Jia P.M., Huang Y., Tang W., Shi G.Y., Sun Y.P., Dai J., Wang Z.Y., Chen S.J., Zhang T.D., Waxman S., Chen Z., Chen G.Q. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J. Natl. Cancer Inst. 1999, 91:772-778.
33. Wei Y., Liu D., Ge Y., Zhou F., Xu J., Chen H., Yun X., Gu J., Jiang J. Down-regulation of beta1,4GalT V at protein level contributes to arsenic trioxide-induced glioma cell apoptosis. Cancer Lett. 2008, 267:96-105.
34. Mann K.K., Colombo M., Miller W.H. Arsenic trioxide decreases AKT protein in a caspase-dependent manner. Mol. Cancer Therapeut. 2008, 7:1680-1687.
35. Dolniak B., Katsoulidis E., Carayol N., Altman J.K., Redig A.J., Tallman M.S., Ueda T., Watanabe-Fukunaga R., Fukunaga R., Platanias L.C. Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2. J. Biol. Chem. 2008, 283:12034-12042.
36. Zhen Y., Zhao S., Li Q., Li Y., Kawamoto K. Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas. Cancer Lett. 2010, 292:64-72.
37. Uslu R., Sanli U.A., Sezgin C., Karabulut B., Terzioglu E., Omay S.B., Goker E. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin. Cancer Res. 2000, 6:4957-4964.
38. Chou W.C., Chen H.Y., Yu S.L., Cheng L., Yang P.C., Dang C.V. Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood 2005, 106:304-310.
39. Neureiter D., Herold C., Ocker M. Gastrointestinal cancer - only a deregulation of stem cell differentiation?. Int. J. Mol. Med. (Rev.) 2006, 17:483-489.
40. Egberts J.H., Schniewind B., Schafmayer C., Kruse M.L., Sipos B., Fandrich F., Kalthoff H., Tepel J. Establishment of a novel orthotopic xenograft model of human gallbladder carcinoma. Clin. Exp. Metast. 2007, 24:141-148.
41. Fan Y.Z., Fu J.Y., Zhao Z.M., Chen C.Q. Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro. Hepatobiliary Pancreat. Dis. Int. 2007, 6:72-80.
42. Mita Y., Ajiki T., Kamigaki T., Okazaki T., Hori H., Horiuchi H., Hirata K., Fujita T., Fujimori T., Kuroda Y. Antitumor effect of gemcitabine on orthotopically inoculated human gallbladder cancer cells in nude mice. Ann. Surg. Oncol. 2007, 14:1374-1380.
43. Alberts S.R., Al-Khatib H., Mahoney M.R., Burgart L., Cera P.J., Flynn P.J., Finch T.R., Levitt R., Windschitl H.E., Knost J.A., Tschetter L.K. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 2005, 103:111-118.
44. Tsuchida A., Itoi T., Aoki T., Koyanagi Y. Carcinogenetic process in gallbladder mucosa with pancreaticobiliary maljunction (review). Oncol. Rep. 2003, 10:1693-1699.